Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials
Articolo
Data di Pubblicazione:
2019
Abstract:
The effect of low-density lipoprotein cholesterol-lowering therapy with alirocumab or evolocumab on individual clinical efficacy and safety endpoints remains unclear. We aimed to evaluate the efficacy and safety of alirocumab and evolocumab in patients with dyslipidaemia or atherosclerotic cardiovascular disease.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Alirocumab; Cholesterol-lowering therapies; Evolocumab; PCSK9
Elenco autori:
Guedeney, Paul; Giustino, Gennaro; Sorrentino, Sabato; Claessen, Bimmer E; Camaj, Anton; Kalkman, Deborah N; Vogel, Birgit; Sartori, Samantha; De Rosa, Salvatore; Baber, Usman; Indolfi, Ciro; Montalescot, Gilles; Dangas, George D; Rosenson, Robert S; Pocock, Stuart J; Mehran, Roxana
Link alla scheda completa:
Pubblicato in: